ID.1
Item
registered patient at mskcc
boolean
C1513120 (UMLS CUI [1])
ID.2
Item
age ≥18 years
boolean
C0001779 (UMLS CUI [1])
ID.3
Item
patients with her2+ metastatic breast cancer (either 3+ by immunohistochemistry or with evidence of gene amplification (>2.0) by fluorescence in situ hybridization (fish))
boolean
C1699634 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
ID.4
Item
measurable or evaluable disease
boolean
C0449385 (UMLS CUI [1])
ID.5
Item
currently taking or about to commence treatment with trastuzumab at a dosing schedule of 2 mg/kg weekly or 6 mg/kg every three weeks, as per standard of care
boolean
C0013216 (UMLS CUI [1,1])
C0728747 (UMLS CUI [1,2])
ID.6
Item
karnofsky performance score ≥ 60
boolean
C0206065 (UMLS CUI [1])
ID.7
Item
signed informed consent
boolean
C0021430 (UMLS CUI [1])
ID.8
Item
previous grade 3 or higher allergic reaction to trastuzumab that resulted in discontinuation of trastuzumab therapy
boolean
C0020517 (UMLS CUI [1,1])
C0728747 (UMLS CUI [1,2])
ID.9
Item
claustrophobia/pain leading to inability to lie still for the duration of the scanning procedure.
boolean
C0008909 (UMLS CUI [1,1])
C0024485 (UMLS CUI [1,2])
ID.10
Item
pregnancy test to be performed on female patients of childbearing potential within 24hrs before administration of radioactive material.
boolean
C0032976 (UMLS CUI [1])
ID.11
Item
inability to provide written informed consent.
boolean
C0021430 (UMLS CUI [1])
ID.12
Item
patients with liver metastases as the only site of distant disease
boolean
C0494165 (UMLS CUI [1])
ID.13
Item
patients with known sensitivity or contraindication to herceptin.
boolean
C0020517 (UMLS CUI [1,1])
C0338204 (UMLS CUI [1,2])